0000000000300098

AUTHOR

Iacopo Macchi

showing 7 related works from this author

Preoperative, Intraoperative and Postoperative Corticosteroid Use as an Adjunctive Treatment for Rhegmatogenous Retinal Detachment

2020

The treatment for rhegmatogenous retinal detachment (RRD) is surgery, including pars plana vitrectomy (PPV) and scleral buckling (SB). Despite surgical advances, degeneration of the photoreceptors and post-operative complications, such as proliferative vitreoretinopathy (PVR), often occurs as the result of inflammation, preventing complete visual recovery or causing RRD recurrence. There is increasing evidence that in the presence of RRD, the activation of inflammatory processes occurs and the surgery itself induces an inflammatory response. This comprehensive review focuses on the use of different formulations of corticosteroids (CCS), as an adjunctive treatment to surgery, either PPV or S…

Pars planamedicine.medical_specialtyProliferative vitreoretinopathyTriamcinolone acetonidemedicine.medical_treatmentvitrectomylcsh:MedicineVitrectomydexamethasoneReviewtriamcinolonecorticosteroids03 medical and health sciences0302 clinical medicinefluocinolonecorticosteroids; dexamethasone; fluocinolone; rhegmatogenous retinal detachment; scleral buckling; triamcinolone; vitrectomyPrednisoneMedicineCorticosteroidscleral bucklingSettore MED/30 - Malattie Apparato Visivobusiness.industrylcsh:Rrhegmatogenous retinal detachmentRetinal detachmentGeneral MedicineFluocinolonemedicine.diseaseeye diseasesSurgerymedicine.anatomical_structureAdjunctive treatment030221 ophthalmology & optometrybusiness030217 neurology & neurosurgerymedicine.drug
researchProduct

Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers

2019

Purpose: To analyse the effects of intravitreal dexamethasone implant (DEX) in patients with diabetic macular oedema (DME) unresponsive to ranibizumab treatment, in relation to the inflammatory optical coherence tomography (OCT) retinal features, subfoveal neuroretinal detachment (SND) and hyperreflective retinal spots (HRS). Methods: Patients with DME poorly responsive to three injections of ranibizumab were treated with DEX. Best-corrected visual acuity (BCVA) and central macula thickness (CMT, measured by Spectralis SD-OCT) were assessed at baseline and at 1, 3, and 6 months. Results: Overall, 44 eyes were included in the study. In the whole group, mean BCVA (baseline 51.5 ± 8.3 letters)…

MaleVisual acuitygenetic structuresVisual AcuityAngiogenesis InhibitorsDrug Implantchemistry.chemical_compound0302 clinical medicineGlucocorticoidMacula LuteaProspective StudiesFluorescein AngiographyProspective cohort studyTomographyDrug Implantsmedicine.diagnostic_testGeneral MedicineDiabetic retinopathyDrug ToleranceFluorescein angiographyTreatment Outcomediabetic macular oedemaIntravitreal InjectionsFemalemedicine.symptomDrugTomography Optical Coherencemedicine.drugAngiogenesis InhibitorHumanmedicine.medical_specialtyFundus Oculibest-corrected visual acuity; dexamethasone; diabetes retinopathy; diabetic macular oedema; optical coherence tomography; ranibizumab; Aged; Angiogenesis Inhibitors; Dexamethasone; Diabetic Retinopathy; Dose-Response Relationship Drug; Drug Implants; Drug Tolerance; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Glucocorticoids; Humans; Intravitreal Injections; Macula Lutea; Macular Edema; Male; Prospective Studies; Ranibizumab; Tomography Optical Coherence; Treatment Outcome; Visual AcuitydexamethasoneMacular EdemaFollow-Up StudieDose-Response Relationship03 medical and health sciencesOphthalmologyRanibizumabmedicineHumansMacular edemaGlucocorticoidsDexamethasoneAgedbest-corrected visual acuity; dexamethasone; diabetes retinopathy; diabetic macular oedema; optical coherence tomography; ranibizumab; Aged; Angiogenesis Inhibitors; Dexamethasone; Diabetic Retinopathy; Dose-Response Relationship; Drug; Drug Implants; Drug Tolerance; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Glucocorticoids; Humans; Intravitreal Injections; Macula Lutea; Macular Edema; Male; Prospective Studies; Ranibizumab; Tomography; Optical Coherence; Treatment Outcome; Visual Acuityoptical coherence tomographyDiabetic RetinopathyDose-Response Relationship Drugbusiness.industryIntravitreal InjectionRetinalmedicine.diseaseeye diseasesOphthalmologyProspective StudiechemistryOptical Coherence030221 ophthalmology & optometrysense organsRanibizumabbusinessdiabetes retinopathy030217 neurology & neurosurgerybest-corrected visual acuityFollow-Up Studies
researchProduct

Vascular changes after vitrectomy for rhegmatogenous retinal detachment: optical coherence tomography angiography study

2020

Purpose: To analyse the postoperative foveal avascular zone (FAZ) area, superficial vessel density (SVD) and deep vessel density (DVD) and their correlation with functional (best-corrected visual acuity, BCVA) and anatomical outcomes (foveal macular thickness, FMT) after surgery for rhegmatogenous retinal detachment (RRD) repair. Method: Patients with RRD eyes, successfully treated with a single pars plana vitrectomy (PPV) with gas tamponade and a minimum 12 months follow-up, were re-examined. Foveal avascular zone (FAZ) area, SVD, DVD and FMT were evaluated by using optical coherence tomography angiography (OCTA) and compared to fellow eye. Results: Fifty-six patients with macula-on and 37…

Pars planamedicine.medical_specialtyVisual acuitygenetic structuresmedicine.medical_treatmentvitrectomyVitrectomyfoveal avascular zone03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFovealOphthalmologyMedicinebusiness.industryrhegmatogenous retinal detachmentRetinal detachmentRetinalGeneral MedicineOptical coherence tomography angiographymedicine.diseaseeye diseasesOphthalmologymedicine.anatomical_structuresuperficial and deep vessel densitychemistry030221 ophthalmology & optometryfoveal avascular zone; rhegmatogenous retinal detachment; superficial and deep vessel density; vitrectomysense organsTamponademedicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study

2022

Aim: To examine the effect of subthreshold micropulse yellow laser (SMYL) on best-corrected visual acuity (BCVA), central macular thickness (CMT), and optical coherence tomography angiography (OCT-A) changes in eyes with persistent diabetic macular edema (DME) after pars plana vitrectomy (PPV) for tractional DME (TDME).Patients and Methods: In a comparative study, 95 eyes of 95 consecutive patients with persistent DME were prospectively enrolled. The SMYL group (54 eyes) was treated with SMYL 6 months after PPV, while the control group (41 eyes) was followed up without treatment. BCVA and CMT by OCT were analyzed at baseline and 3 and 6 months. Additionally, parameters such as the vessel de…

Pharmacologydiabetic retinopathySettore MED/30 - Malattie Apparato VisivoinflammationOCT angiographysubthreshold micropulse laserPharmacology (medical)OCT angiography; diabetic retinopathy; inflammation; subthreshold micropulse laser; tractional DMEtractional DME
researchProduct

Optical coherence tomography angiography evaluation of peripapillary microvascular changes after rhegmatogenous retinal detachment repair

2021

PURPOSE To evaluate the radial peripapillary capillary plexus (RPCP) vessel density (VD) and the retinal nerve fiber layer (RNFL) thickness in eyes successfully treated with pars plana vitrectomy for primary rhegmatogenous retinal detachment. METHODS In this cross-sectional multicenter clinical study, eyes with a minimum 12-month follow-up were reexamined. The RPCP VD and RNFL thickness in the rhegmatogenous retinal detachment subfields of the affected eye (study group) were compared with the corresponding areas of the healthy fellow eyes (control group). RESULTS Fifty-three eyes were included in the study. A significantly lower RPCP VD and RNFL thickness were observed in those subfields af…

MaleRetinal Ganglion Cellsgenetic structuresComputed Tomography Angiographymedicine.medical_treatmentNerve fiber layerVisual AcuityVitrectomyEyeradial peripapillary capillary plexuschemistry.chemical_compoundNerve FibersVitrectomyTomographyRetinal detachment repairRetinal detachmentGeneral MedicineMiddle AgedAxial Length Eyemedicine.anatomical_structureFemaleTomography Optical CoherencePars planamedicine.medical_specialtyBiometryOptic DiskEndotamponaderetinal detachmentOCT-angiography; Radial peripapillary capillary plexus; Retinal detachment; Retinal nerve fiber layer; Aged; Axial Length Eye; Biometry; Cross-Sectional Studies; Endotamponade; Female; Humans; Male; Middle Aged; Nerve Fibers; Optic Disk; Retinal Detachment; Retinal Ganglion Cells; Retinal Vessels; Retrospective Studies; Visual Acuity; Computed Tomography Angiography; Tomography Optical Coherence; VitrectomyOphthalmologymedicineHumansAxial LengthAgedRetrospective StudiesRetinabusiness.industryradial peripapillary capillary plexus; OCT-angiography; retinal nerve fiber layer; retinal detachmentRetinal Vesselsretinal nerve fiber layerRetinalOptical coherence tomography angiographymedicine.diseaseeye diseasesOphthalmologyCross-Sectional StudieschemistryOptical Coherencesense organsOCT-angiographybusiness
researchProduct

Widening use of dexamethasone implant for the treatment of macular edema

2017

Vincenza Bonfiglio, Michele Reibaldi, Matteo Fallico, Andrea Russo, Alessandra Pizzo, Stefano Fichera, Carlo Rapisarda, Iacopo Macchi, Teresio Avitabile, Antonio Longo Department of Ophthalmology, University of Catania, Catania, Italy Abstract: Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis. The implant is formulated in a biodegradable copolymer to release the active ingredient within the vitreous chamber for up to 6 months after an intravitreal injection, allowing a prolonged interval of effica…

3003intravitrealgenetic structuresimplantmedicine.medical_treatmentPharmaceutical ScienceVitrectomyReviewDrug Implantcorticosteroids0302 clinical medicineGlucocorticoidCentral retinal vein occlusionDrug DiscoveryDelayed-Action PreparationCorticosteroidRandomized Controlled Trials as TopicDrug ImplantsCorticosteroids; Dexamethasone; Implant; Intravitreal; Macular edema; Pharmacology; 3003; Drug Discovery3003 Pharmaceutical ScienceDiabetic retinopathyIntravitreal InjectionsUveitismedicine.drugHumanmedicine.medical_specialtydexamethasone03 medical and health sciencesOphthalmologymedicineHumansMacular edemaGlucocorticoidsDexamethasonePharmacologyMacular edemaDiabetic Retinopathybusiness.industryIntravitreal InjectionDrug Discovery3003 Pharmaceutical Sciencelcsh:RM1-950Macular degenerationmedicine.diseaseeye diseasesSurgerylcsh:Therapeutics. PharmacologyDelayed-Action Preparations030221 ophthalmology & optometryBranch retinal vein occlusionsense organsbusiness030217 neurology & neurosurgeryDrug Design, Development and Therapy
researchProduct

OCT-Angiography evaluation of peripapillary microvascular changes after rhegmatogenous retinal detachment repair

2021

Purpose: To evaluate the radial peripapillary capillary plexus (RPCP) vessel density (VD) and the retinal nerve fiber layer (RNFL) thickness in eyes successfully treated with pars plana vitrectomy for primary rhegmatogenous retinal detachment. Methods: In this cross-sectional multicenter clinical study, eyes with a minimum 12-month follow-up were reexamined. The RPCP VD and RNFL thickness in the rhegmatogenous retinal detachment subfields of the affected eye (study group) were compared with the corresponding areas of the healthy fellow eyes (control group). Results: Fifty-three eyes were included in the study. A significantly lower RPCP VD and RNFL thickness were observed in those subfields…

Retinal nerve fiber layerRadial peripapillary capillary plexusOCT-Angiography
researchProduct